SAN DIEGO, Nov. 19 /PRNewswire-FirstCall/ -- Somaxon Pharmaceuticals, Inc. today said that, tomorrow morning, Monday, November 20, the company plans to issue results from its Phase 3 clinical trial of SILENOR(TM) (doxepin HCl) for the treatment of insomnia in elderly patients. Additionally, Somaxon management will host a conference call Monday morning at 9:00 a.m. Eastern Time to review the results of this Phase 3 trial.
Callers may participate in the conference call by dialing (800) 240-4186 (domestic) or (303) 262-2138 (international). A telephonic replay will be available for approximately one week following the conclusion of the call by dialing (800) 405-2236 (domestic) or (303) 590-3000 (international), and entering passcode 11077311#. The conference call also will be available to interested parties through a live audio Internet broadcast at www.somaxon.com and www.opencompany.info. The call will be archived and accessible at both sites for approximately one year.
About Somaxon Pharmaceuticals, Inc.
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon’s lead product candidate, SILENOR(TM) (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for pathological gambling and has completed a pilot Phase 2 trial for smoking cessation. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.
For more information, please visit the company’s web site at www.somaxon.com.
Contacts: Meg McGilley Chief Financial Officer (858) 480-0402 Rob Whetstone PondelWilkinson, Inc. (310) 279-5963
Somaxon Pharmaceuticals, Inc.
CONTACT: Meg McGilley, Chief Financial Officer of Somaxon Pharmaceuticals,Inc., +1-858-480-0402; or Rob Whetstone of PondelWilkinson, Inc.,+1-310-279-5963, for Somaxon Pharmaceuticals, Inc.
